Skip to main content
Premium Trial:

Request an Annual Quote

Jury Sides with Life Tech in Second Phase of IP Suit with Illumina

NEW YORK (GenomeWeb News) – Life Technologies said today that a jury in the US District Court for the Northern District of California has decided in its favor in the second phase of an ongoing patent-infringement suit with Illumina.

After a seven day trial, the jury unanimously decided that Life Tech's Applied Biosystems SOLiD sequencing technology does not infringe a patent at the heart of the dispute, the company said.

Illumina had alleged that the SOLiD system infringed US Patent Nos. 5,969,119; 5,750,341; and 6,306,597. The court had already ruled in August that ABI does not infringe the asserted claims of the '341 and '597 patents. The jury decision announced today clears ABI of infringing the '119 patent.

Kip Miller, president of the genetic systems division at Life Technologies, said in a statement that the company is "pleased" with the decision, which "validate[s] our belief that the SOLiD sequencing system is unique in its design."

Earlier this month, Illumina won the first phase of the trial, in which the jury found that Illumina owns the patents that are the subject of the suit.

An Illumina spokesperson was not available for comment.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.